
Sign up to save your podcasts
Or


How do you measure disease progression in a highly variable and heterogeneous clinical population, such as amyotrophic lateral sclerosis (ALS)? Can plasma creatinine act as a robust surrogate biomarker in clinical trials? Dr. Ruben P A van Eijk (University Medical Center, Utrecht, The Netherlands) discusses this month’s editor’s choice. Read the full paper here: http://jnnp.bmj.com/content/89/2/156.
By BMJ Group4.6
88 ratings
How do you measure disease progression in a highly variable and heterogeneous clinical population, such as amyotrophic lateral sclerosis (ALS)? Can plasma creatinine act as a robust surrogate biomarker in clinical trials? Dr. Ruben P A van Eijk (University Medical Center, Utrecht, The Netherlands) discusses this month’s editor’s choice. Read the full paper here: http://jnnp.bmj.com/content/89/2/156.

136 Listeners

320 Listeners

495 Listeners

36 Listeners

50 Listeners

302 Listeners

5 Listeners

8 Listeners

5 Listeners

3 Listeners

2 Listeners

3 Listeners

40 Listeners

15 Listeners

1 Listeners

49 Listeners

0 Listeners

6 Listeners

14 Listeners

3 Listeners

12 Listeners

3 Listeners

22 Listeners

23 Listeners

24 Listeners

132 Listeners

50 Listeners

179 Listeners

6 Listeners

823 Listeners

80 Listeners